- BIBF 1120 Angiogenesis Inhibitor Oncolytic
[作者:Hilberg, F; Roth, GJ; Merger, M; Kaiser, R,期刊:Drugs of the Future, 页码:5-10 , 文章类型: Article,,卷期:2010年35-1]
- Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a fundamental process for tumor growth and metastasis. BIBF 1120 (planned brand name Vargatef (TM)) is a novel, oral, potent angiokinase ...
- HIGH-DENSITY LIPOPROTEIN MODULATION TARGETS
[作者:Mousa, SS; Block, RC; Mousa, SA,期刊:Drugs of the Future, 页码:33-39 , 文章类型: Review,,卷期:2010年35-1]
- Given the strong genetic determinants of favorable high-density lipoprotein cholesterol (HDL-C) levels, the ability to achieve the cardiovascular and longevity benefits associated with this mediator of the reverse choles...
- THERAPEUTIC STRATEGIES IN CACHEXIA: CURRENT AND FUTURE DIRECTIONS
[作者:Argiles, JM; Sirisi, S; Lopez-Soriano, FJ; Busquets, S,期刊:Drugs of the Future, 页码:41-52 , 文章类型: Review,,卷期:2010年35-1]
- Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities, such as glucose intolerance, fat depletion and muscle protein catabolism. The aim of the present ar...
- APPROACHES TO ASSESSING DRUG SAFETY IN THE DISCOVERY PHASE HIGHLIGHTS OF THE SOCIETY FOR MEDICINES RESEARCH SYMPOSIUM HELD ON SEPTEMBER 24TH, 2009, AT THE NATIONAL HEART & LUNG INSTITUTE, KENSINGTON, LONDON, UK
[作者:Allen, J; Jeffrey, P; Williams, R; Ratcliffe, AJ,期刊:Drugs of the Future, 页码:67-75 , 文章类型: Article,,卷期:2010年35-1]
- The Society for Medicines Research symposium, sponsored by Apredica, Cwathmey Preclinical Services, Gentronix and Cyprotex, was held at the National Heart and Lung Institute, Kensington, London, U.K. The meeting, organiz...
|